FINWIRES · TerminalLIVE
FINWIRES

Neurocrine Biosciences Should See More Upside on Crenessity Growth, RBC Says

By

Neurocrine Biosciences (NBIX) could see more upside from wider Crenessity use, easing insurance limits, stronger patient demand and likely commercial product beats in 2026, RBC Capital Markets said in a note Friday.

RBC said its survey of 35 endocrinologists showed Crenessity still has room to grow after a strong Q1, even as some investors worry near-term demand may slow as surveyed doctors now use Crenessity in about 23% of their Congenital Adrenal Hyperplasia patients on average and expect usage to reach 37% by the end of 2026.

The firm raised its 2026 Crenessity sales estimate to $750 million from $734 million, above the roughly $650 million consensus estimate, saying the target looks achievable even with more cautious growth assumptions and longer-term demand also looks strong, with doctors expecting to use Crenessity in just over half of their CAH patients within five years.

Insurance approvals remain the main barrier to wider use, but RBC expects those issues to ease over time and support further adoption, according to the note.

RBC kept the company's outperform rating and raised its price target to $183 from $180.

Price: $157.29, Change: $+0.90, Percent Change: +0.58%

Related Articles

Wire

Estrella Resources Says Electromagnetic Survey Completed at East Timor Manganese Project; Shares Up 4%

Estrella Resources (ASX:ESR) said an unmanned aerial vehicle passive electromagnetic geophysical survey was completed at its Ira Miri manganese project in East Timor, according to a Friday Australian bourse filing.Results from the survey are expected to rank and prioritize deeper drill targets beneath and adjacent to the current Ira Miri pit as well as refine the company's geological and structural model of the Ira Miri manganese system, per the filing.The company's shares rose nearly 4% in recent trading on Friday.

ASX:ESR
Wire

Nextpower to Acquire Prevalon Energy, Raises Fiscal 2027 Outlook; Shares Gain After Hours

Nextpower (NXT) agreed to acquire Prevalon Energy, a US joint venture between Mitsubishi Power Americas and EES, for up to $365 million in cash and stock to expand into battery storage and AI data-center infrastructure markets.The transaction is expected to close in Q2 of fiscal 2027, Nextpower said Thursday in a statement.The company also raised fiscal 2027 guidance to adjusted diluted EPS of $4.30 to $4.73 on revenue of $4 billion to $4.4 billion. The prior outlook was EPS of $3.19 to $3.56 on revenue of $3.8 billion to $4.1 billion.Analysts polled by FactSet expect EPS of $4.54 on revenue of $4 billion.Nextpower shares rose 7.9% in after-hours trading.

$NXT
Wire

Gap Fiscal Q1 GAAP Earnings, Revenue Rise

Gap (GAP) reported fiscal Q1 adjusted earnings late Thursday of $0.38 per diluted share. The company did not provide comparable adjusted earnings for the year-ago quarter. Analysts polled by FactSet expected $0.37.The company reported GAAP earnings of $0.90 per diluted share, up from $0.51 a year earlier.Revenue for the 13 weeks ended May 2 was $3.50 billion, up from $3.46 billion a year earlier.Analysts surveyed by FactSet expected $3.52 billion.For Q2, the company expects net sales to be flat to down 1% year-over-year.For fiscal 2026, the company now expects adjusted EPS of $2.30 to $2.40, up from the prior forecast of $2.20 to $2.35. Analysts expect $2.29.The company now expects fiscal 2026 net sales to be up 1% to 2% year-over-year, versus the prior outlook for 2% to 3% growth.

$GAP